Pancreas

Lancet. 2022;399(10338):1867–75

Smits FJ, Henry AC, Besselink MG, Busch OR, van Eijck CH, Arntz M, Bollen TL, van Delden OM, van den Heuvel D, van der Leij C, van Lienden KP, Moelker A, Bonsing BA, Borel Rinkes IH, Bosscha K, van Dam RM, Derksen WJM, den Dulk M, Festen S, Groot Koerkamp B, de Haas RJ, Hagendoorn J, van der Harst E, de Hingh IH, Kazemier G, van der Kolk M, Liem M, Lips DJ, Luyer MD, de Meijer VE, Mieog JS, Nieuwenhuijs VB, Patijn GA, te Riele WW, Roos D, Schreinemakers JM, Stommel MWJ, Wit F, Zonderhuis BA, Daamen LA, van Werkhoven CH, Molenaar IQ, van Santvoort HC; Dutch Pancreatic Cancer Group

Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: An open-label, nationwide, stepped-wedge cluster-randomized trial


Background: Early recognition and management of postoperative complications, before they become clinically relevant, can improve postoperative outcomes for patients, especially for high-risk procedures such as pancreatic resection.
Methods: The authors did an open-label, nationwide, stepped-wedge cluster-randomized trial that included all patients having pancreatic resection during a 22-month period in the Netherlands. In this trial design, all 17 centers that did pancreatic surgery were randomly allocated for the timing of the crossover from usual care (the control group) to treatment given in accordance with a multimodal, multidisciplinary algorithm for the early recognition and minimally invasive management of postoperative complications (the intervention group). Randomization was done by an independent statistician using a computer-generated scheme, stratified to ensure that low-medium-volume centers alternated with high-volume centers. Patients and investigators were not masked to treatment. A smartphone app was designed that incorporated the algorithm and included the daily evaluation of clinical and biochemical markers. The algorithm determined when to do abdominal computed tomography, radiological drainage, start antibiotic treatment, and remove abdominal drains. After crossover, clinicians were trained in how to use the algorithm during a 4-week wash-in period; analyses comparing outcomes between the control group and the intervention group included all patients other than those having pancreatic resection during this wash-in period. The primary outcome was a composite of bleeding that required invasive intervention, organ failure, and 90-day mortality, and was assessed by a masked adjudication committee.
Findings: From January 8, 2018, to November 9, 2019, all 1805 patients who had pancreatic resection in the Netherlands were eligible for and included in this study. 57 patients who underwent resection during the wash-in phase were excluded from the primary analysis. 1748 patients (885 receiving usual care and 863 receiving algorithm-centered care) were included. The primary outcome occurred in fewer patients in the algorithm-centered care group than in the usual care group (73 [8%] of 863 patients vs. 124 [14%] of 885 patients; adjusted risk ratio [aRR] = 0.48, 95% confidence interval [CI]: 0.38–0.61; p < 0.0001). Among patients treated according to the algorithm, compared with patients who received usual care there was a decrease in bleeding that required intervention (47 [5%] patients vs. 51 [6%] patients; aRR = 0.65, 95% CI: 0.42–0.99; p = 0.046), organ failure (39 [5%] patients vs. 92 [10%] patients; aRR = 0.35, 95% CI: 0.20–0.60; p = 0.0001), and 90-day mortality (23 [3%] patients vs. 44 [5%] patients; aRR = 0.42, 95% CI: 0.19–0.92; p = 0.029).

Interpretation: The algorithm for the early recognition and minimally invasive management of complications after pancreatic resection considerably improved clinical outcomes compared with usual care. This difference included an approximate 50% reduction in mortality at 90 days.

Prof. Dr. H.C. van Santvoort, Department of Surgery, Regional Academic Cancer Center Utrecht, St. Antonius Hospital Nieuwegein and University Medical Center Utrecht, Utrecht, The Netherlands,
E-Mail: h.vansantvoort@umcutrecht.nl

DOI: DOI: 10.1016/s0140-6736(22)00182-9

Back to overview

this could be of interest:

Optimal timing of cholecystectomy after necrotizing biliary pancreatitis

Gut. 2022;71(5):974–82

Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the Dutch randomized PREOPANC trial

J Clin Oncol. 2022;40(11):1220–30

More articles on the topic